Featured Tickers:
Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in TransMedics Group, Inc., AtriCure or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how TransMedics Group, Inc., AtriCure and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About TransMedics Group, Inc., AtriCure and Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Latest Health Care Equipment & Supplies and TransMedics Group, Inc., AtriCure, Inc. Stock News
As of December 11, 2025, TransMedics Group, Inc. had a $4.4 billion market capitalization, compared to the Health Care Equipment & Supplies median of $315.2 million. TransMedics Group, Inc.’s stock is NA in 2025, NA in the previous five trading days and up 82.81% in the past year.
Currently, TransMedics Group, Inc.’s price-earnings ratio is 50.3. TransMedics Group, Inc.’s trailing 12-month revenue is $566.4 million with a 16.2% net profit margin. Year-over-year quarterly sales growth most recently was 32.2%. Analysts expect adjusted earnings to reach $2.581 per share for the current fiscal year. TransMedics Group, Inc. does not currently pay a dividend.
Currently, AtriCure, Inc. does not have a price-earnings ratio. AtriCure, Inc.’s trailing 12-month revenue is $518.3 million with a -5.6% net profit margin. Year-over-year quarterly sales growth most recently was 15.9%. Analysts expect adjusted earnings to reach $-0.239 per share for the current fiscal year. AtriCure, Inc. does not currently pay a dividend.
How We Compare TransMedics Group, Inc., AtriCure and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at TransMedics Group, Inc., AtriCure and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions